Summary • Vor Biopharma Inc. (VOR) rises 15.9% in intraday trading to $11.97 following Q3 earnings report. • Q3 results show ...

Nostradamus is said to have predicted a number of major global events in his work Les Propheties - and he has some chilling ...

The media could not be loaded, either because the server or network failed or because the format is not supported.

Summary • Vor Biopharma Inc. shares rose 11.6% to $8.40 after reporting third-quarter financial results showing a ...

Hyperbaric Oxygen Therapy (HBOT) is emerging as a science-backed tool to boost brain performance, reverse decline, and ...

Vor Biopharma's estimated fair value is US$15.10 based on 2 Stage Free Cash Flow to Equity. Vor Biopharma is estimated to be 49% undervalued based on current share p ...

After crossing the OAB VOR, the pilot will head outbound on a 298-degree track. After passing the THOWL waypoint outbound, the pilot may descend to 7,600 feet and will execute a procedure turn (PT) ...

Vor Biopharma (VOR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

BOSTON, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today reported financial results for the ...

China biotech RemeGen and its new U.S. partner Vor Bio are on a roll with their first-in-class autoimmune treatment telitacicept. Two weeks after RemeGen revealed the success of a China phase 3 trial ...

Vor Bio’s big bet on RemeGen’s autoimmune asset telitacicept appears well placed after the drug—already approved across three conditions overseas—delivered a late-stage win in a Sjögren's syndrome ...